Page last updated: 2024-08-22

vidarabine and rolipram

vidarabine has been researched along with rolipram in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J	1
Everett, PC; Lerner, A; Makkinje, A; Meyers, JA; Rabbi, M	1

Trials

1 trial(s) available for vidarabine and rolipram

Article	Year
Preclinical assessment of curcumin as a potential therapy for B-CLL. American journal of hematology, 2007, Volume: 82, Issue:1 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine	2007

Article

Year

Preclinical assessment of curcumin as a potential therapy for B-CLL.

American journal of hematology, 2007, Volume: 82, Issue:1

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Curcumin; Cyclic Nucleotide Phosphodiesterases, Type 4; Dexamethasone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; NF-kappa B; NF-kappaB-Inducing Kinase; PPAR gamma; Protein Serine-Threonine Kinases; Rolipram; Signal Transduction; Tumor Cells, Cultured; Vidarabine; Vincristine

2007

Other Studies

2 other study(ies) available for vidarabine and rolipram

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. Leukemia, 2001, Volume: 15, Issue:10 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine	2001

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

Leukemia, 2001, Volume: 15, Issue:10

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine

2001